Merck and Eisai Announce Promising Interim Results from LEAP-015 Trial of KEYTRUDA® and LENVIMA® in HER2-Negative Gastroesophageal Adenocarcinoma

 Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai announced results from the Phase 3 LEAP-015 trial evaluating KEYTR...

January 27, 2025 | Monday | News
Pfizer's BRAFTOVI® Combination Therapy Demonstrates Significant Clinical Benefit in Metastatic Colorectal Cancer with BRAF V600E Mutation

 Pfizer Inc. (NYSE: PFE) announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® (encorafenib) in combination ...

January 27, 2025 | Monday | News
Abyssinia Biosciences and Cordance Medical Partner to Explore Focused Ultrasound for Alzheimer's Diagnosis and Treatment

Abyssinia Biosciences and Cordance Medical announced  that they have entered into a collaborative agreement to explore focused ultrasound in diagnosti...

January 24, 2025 | Friday | News
CG Pharmaceuticals Presents Promising Results for Ivaltinostat in Metastatic Pancreatic Cancer at ASCO GI Symposium

CG Pharmaceuticals (CG Pharma), a clinical biopharmaceutical company located in the San Francisco Bay Area, was established as an independent entity i...

January 24, 2025 | Friday | News
AbbVie and Neomorph Forge Partnership to Develop Novel Molecular Glue Degraders for Oncology and Immunology

AbbVie (NYSE: ABBV) and Neomorph, Inc. announced a collaboration and option-to-license agreement to develop novel molecular glue degraders for multiple tar...

January 24, 2025 | Friday | News
AstraZeneca Announces C$820 Million Investment in Ontario, Creating Over 700 High-Skilled Jobs

AstraZeneca, a global pharmaceutical company focused on developing life changing medicines,  announced a C$820 million (US$570m) investment in Canada,...

January 24, 2025 | Friday | News
Akeso’s Cadonilimab Combination Therapy Shows Landmark Survival Benefits in Advanced Gastric Cancer, Published in Nature Medicine

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that the prestigious medical journal Nature Medicine published the results of ...

January 23, 2025 | Thursday | News
EU Approves Sarclisa in Combination with VRd for Newly Diagnosed Multiple Myeloma Patients Ineligible for Stem Cell Transplant

Following the adoption of a positive opinion by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP)...

January 23, 2025 | Thursday | News
Xilio Therapeutics Presents Promising Phase 2 Data for Vilastobart in Combination with Atezolizumab in Metastatic MSS Colorectal Cancer

Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies fo...

January 23, 2025 | Thursday | News
Stuart Therapeutics Completes Phase III Study of ST-100 for Dry Eye Disease, Topline Data Expected in February 2025

Stuart Therapeutics, Inc. (Stuart), a clinical-stage drug platform company developing novel therapies for ophthalmic diseases,  announced last patient...

January 23, 2025 | Thursday | News
Gilead Receives FDA Approval for Yescarta® Label Update, Showing Significant Overall Survival Benefit in Second-Line Treatment for Large B-Cell Lymphoma

Kite, a Gilead Company (Nasdaq: GILD), announced that the U.S. Food and Drug Administration (FDA) has approved a label update for Yescarta® (axica...

January 23, 2025 | Thursday | News
IMPACT Therapeutics' Senaparib Capsules Receive NMPA Approval for Maintenance Treatment of Advanced Ovarian Cancer in China

 IMPACT Therapeutics ("IMPACT"), a biopharmaceutical company focusing on the discovery and development of targeted anti-cancer therapeutics based on s...

January 20, 2025 | Monday | News
OS Therapies Announces Positive Phase 2b Results for OST-HER2 in Preventing Recurrence of Lung Metastatic Osteosarcoma

OS Therapies, Inc. (NYSE-A: OSTX), a clinical-stage biotechnology company advancing immunotherapies and targeted drug conjugates for cancer treatment, ...

January 17, 2025 | Friday | News
Solid Biosciences Advances Toward Transformative Genetic Medicines with Expanded Pipeline and New Clinical Milestones

Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines fo...

January 17, 2025 | Friday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close